<DOC>
	<DOCNO>NCT02493855</DOCNO>
	<brief_summary>This study ombitasvir/ABT-450/ritonavir dasabuvir low dose ribavirin ( RBV ) , full dose RBV RBV add treatment naive subject chronic Hepatitis C Virus ( HCV ) .</brief_summary>
	<brief_title>Ombitasvir/ABT-450/Ritonavir ( Ombitasvir/ABT-450/r ) Dasabuvir Therapy With Low Dose Ribavirin ( RBV ) , Full Dose RBV RBV Add-On Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults</brief_title>
	<detailed_description>A study evaluate effect RBV second phase plasma HCV ribonucleic acid ( RNA ) decline subject receive ombitasvir/ABT-450/ritonavir dasabuvir full dose RBV compare ombitasvir/ABT-450/ritonavir low dose RBV without RBV treatment-naive HCV genotype ( GT ) 1a-infected adult subject .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>1 . Screening laboratory result indicate HCV genotype 1 ( GT1 ) infection . 2 . Chronic HCV infection . 3 . Subjects must noncirrhotic . 4 . Subjects must able understand adhere study visit schedule protocol requirement well voluntarily sign date institutional review board ( IRB ) approve informed consent . 1 . Women pregnant breastfeeding . 2 . Positive test result hepatitis B surface antigen ( HBsAg ) antihuman immunodeficiency virus antibody ( HIV Ab ) positive immunoassay . 3 . Clinically significant abnormality comorbidities , HCV infection , make subject unsuitable study treatment . 4 . Current enrollment another interventional clinical study . Previous use HCV treatment include pegylated interferon ( pegIFN ) , ribavirin , direct act antiviral agent , either investigational approved , HCV include protease inhibitor , nucleoside nonnucleoside polymerase inhibitor , NS5A inhibitor . 5 . History solid organ transplant . 6 . Screening laboratory analysis show abnormal result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Hepatitis C Genotype 1a</keyword>
	<keyword>Interferon free</keyword>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Treatment naive</keyword>
	<keyword>HCV</keyword>
</DOC>